theScore To Report Q2 F2021 Financial Results on Tuesday, April 13, 2021
06 Abril 2021 - 6:45AM
Business Wire
Score Media and Gaming Inc.
(“theScore” or the “Company”) (TSX: SCR; NASDAQ: SCR) will release
its Q2 F2021 financial results after 5:00pm ET on
Tuesday, April 13, 2021.
theScore will host a conference call
and webcast at 5:30pm ET that day where management will
review the Company’s results, followed by a Q&A session with
analysts.
Conference Call Dial-In:
Toll Free North America: +1 (844) 925-3583
International: +1 (236) 714-3374 Conference ID: 5097437
The conference call will also be webcast live. Register now
here.
About Score Media and Gaming
Inc.
Score Media and Gaming Inc. empowers millions of sports fans
through its digital media and sports betting products. Its media
app ‘theScore’ is one of the most popular in North America,
delivering fans highly personalized live scores, news, stats, and
betting information from their favorite teams, leagues, and
players. The Company’s sports betting app ‘theScore Bet’ delivers
an immersive and holistic mobile sports betting experience and is
currently available to place wagers in New Jersey, Colorado,
Indiana and Iowa. Publicly traded on the Toronto Stock Exchange
(TSX: SCR) and the Nasdaq Global Select Market (NASDAQ:SCR),
theScore also creates and distributes innovative digital content
through its web, social and esports platforms.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210406005271/en/
Dan Sabreen Director, Communications Score Media and Gaming Inc.
Tel: 917-722-3888 ext. 706 Email: dan.sabreen@thescore.com
Alvin Lobo Chief Financial Officer Score Media and Gaming Inc.
Tel: 416-479-8812 Email: IR@thescore.com
Richard Land, James Leahy JCIR Tel: 212-835-8500 Email:
scr@jcir.com
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sciele Pharma (MM) (NASDAQ): 0 recent articles
Más de Sciele Pharma (MM) Artículos de Noticias